Stockscreener 앱 받기
0.53
0.95%
0.005
전일 마감가:
$0.525
열려 있는:
$0.5171
하루 거래량:
246.55K
Relative Volume:
0.14
시가총액:
$4.09M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-9.40%
1개월 성능:
-33.70%
6개월 성능:
-97.57%
1년 성능:
-99.44%
1일 변동 폭
$0.5158
$0.535
1주일 범위
$0.4901
$0.62
52주 변동 폭
$0.4901
$109.00
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
명칭
Cero Therapeutics Holdings Inc
전화
650-407-2376
주소
201 HASKINS WAY, SOUTH SAN FRANCISCO
CERO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
0.53 | 3.26M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Cero Therapeutics Holdings Inc 주식(CERO)의 최신 뉴스
CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at Maxim Group - Defense World
Maxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq
Maxim Group sets Cero Therapeutics stock with $3 target By Investing.com - Investing.com Nigeria
CERO Therapeutics (CERO) Receives 'Buy' Rating from Maxim Group | CERO Stock News - GuruFocus
Maxim Group sets Cero Therapeutics stock with $3 target - Investing.com
CeroTherapeutics (CERO) Receives Buy Rating from Maxim Analyst | CERO Stock News - GuruFocus
Cero Therapeutics (CERO) Gains Buy Rating with Innovative T-Cell Therapy | CERO Stock News - GuruFocus
CERo Therapeutics (NASDAQ:CERO) Stock Price Up 1.5% – Here’s What Happened - Defense World
CERO THERAPEUTICS HOLDINGS, INC. SEC 10-Q Report - TradingView
Pre-market Movers: LUCY, ALUR, PLRZ, AXDX... - RTTNews
CERo Therapeutics regains Nasdaq compliance - MSN
CERo Therapeutics Regains Nasdaq Compliance with Stockholder Equity - TipRanks
CERo Therapeutics regains Nasdaq compliance, eyes trials - Investing.com Australia
CERo Therapeutics regains Nasdaq compliance, eyes trials By Investing.com - Investing.com South Africa
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1) - The Manila Times
CERo Therapeutics Regains Compliance with Nasdaq Listing Rule Following Successful Fundraising Efforts - Nasdaq
CERo Therapeutics Holdings Inc (NASDAQ: CERO): Blank Check On Growth? - Stocksregister
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity - ADVFN
CERo Therapeutics begins phase 1 trial for leukemia treatment - Investing.com Australia
CERo Therapeutics Initiates Phase 1 Clinical Trial for CER-1236 at TriStar Centennial Medical Center to Treat Acute Myeloid Leukemia - Nasdaq
Cero Therapeutics Announces Tristar Centennial Medical Center As A Clinical Trial Site For Its Phase 1 Clinical Trial Of Cer-1236 In Acute Myeloid Leukemia - marketscreener.com
CERo Therapeutics Holdings, Inc. Announces TriStar - GlobeNewswire
Leading Cancer Center to Test Revolutionary AML Treatment: CERo's Novel T Cell Therapy Enters Clinical Trial - Stock Titan
CERo Therapeutics Holdings Inc (CERO) Stock: A Year of Market Movement, Down and Up - investchronicle.com
CERo Therapeutics announces up to $8M Series D financing; shares up - MSN
CERo Therapeutics Holdings Inc [CERO] is -81.50% lower this YTD. Is it still time to buy? - dbtnews.com
Market cap of Crown LNG Holdings Limited [CGBS] reaches 59.64M – now what? - dbtnews.com
New Providence Acquisition Corp III [NPACU] Stock trading around $10.02 per share: What’s Next? - dbtnews.com
A company insider recently sold 50,896 shares of OppFi Inc [OPFI]. Should You Sale? - knoxdaily.com
CERo Therapeutics Holdings Inc [CERO] Records 50-Day SMA of $1.1308 - knoxdaily.com
CERo Therapeutics Holdings, Inc. to Present Poster on Lead - GlobeNewswire
Breakthrough Leukemia Treatment: CERo's First-in-Human Trial Results Revealed at ASCO 2025 - Stock Titan
Holdings of CERo Therapeutics Holdings Inc (CERO) are aligned with the stars - Sete News
CERo Therapeutics Holdings Inc’s Market Journey: Closing Strong at 1.11, Up 38.85 - DWinneX
Market Momentum: Haoxin Holdings Ltd (HXHX) Registers a 16.47 Increase, Closing at 1.98 - DWinneX
CERo Therapeutics (NASDAQ:CERO) Upgraded at D Boral Capital - Defense World
CERo Therapeutics begins Phase 1 trial for AML treatment By Investing.com - Investing.com South Africa
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat ResultsASGN (NYSE:ASGN), Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook - Benzinga
CERo Therapeutics Holdings Inc (CERO)’s stock price range in the last year - uspostnews.com
CERo Therapeutics begins Phase 1 trial for AML treatment - Investing.com
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia - The Manila Times
CERo Therapeutics Announces Clinical Trial Partnership with Sarah Cannon Research Institute for Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia - Nasdaq
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon - GlobeNewswire
Major Blood Cancer Center Joins CERo's Novel AML Treatment Trial, June Dosing Planned - Stock Titan
CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at D. Boral Capital - Defense World
Boral Capital sets Cero Therapeutics stock with Buy rating - Investing.com Australia
CERo Therapeutics secures $8 million in funding for cancer therapy By Investing.com - Investing.com South Africa
What Are You Thinking About Investing In CERo Therapeutics Holdings Inc (NASDAQ: CERO) Stock? - Stocksregister
CERo Therapeutics Raises Up To $8 Mln To Advance T Cell Therapy Programs - Nasdaq
D. Boral Capital Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq
Cero Therapeutics Holdings Inc (CERO) 재무 분석
Cero Therapeutics Holdings Inc (CERO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Cero Therapeutics Holdings Inc 주식 (CERO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| YK Bioventures Opportunities G | 10% Owner |
Dec 13 '24 |
Sale |
0.06 |
2,998,908 |
179,934 |
13,005,169 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 12 '24 |
Sale |
0.07 |
1,614,541 |
113,018 |
16,004,077 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 11 '24 |
Sale |
0.08 |
1,343,801 |
107,504 |
17,618,618 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 06 '24 |
Sale |
0.12 |
1,236,874 |
148,425 |
21,383,909 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 10 '24 |
Sale |
0.09 |
1,570,947 |
141,385 |
18,962,419 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 09 '24 |
Sale |
0.11 |
850,543 |
93,560 |
20,533,366 |
| SLOAN STUART M | 10% Owner |
Sep 25 '24 |
Sale |
0.10 |
532,486 |
55,538 |
21,067,956 |
| YK Bioventures Opportunities G | 10% Owner |
Oct 10 '24 |
Sale |
0.10 |
3,250,000 |
325,000 |
22,620,783 |
17.27%
1.06%
자본화:
|
볼륨(24시간):